Literature DB >> 12119247

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

Roland Wensel1, Christian F Opitz, Stefan D Anker, Jörg Winkler, Gert Höffken, Franz X Kleber, Rakesh Sharma, Manfred Hummel, Roland Hetzer, Ralf Ewert.   

Abstract

BACKGROUND: Primary pulmonary hypertension (PPH) is a life-threatening disease. Prognostic assessment is an important factor in determining medical treatment and lung transplantation. Whether cardiopulmonary exercise testing data predict survival has not been reported previously. METHODS AND
RESULTS: We studied 86 patients with PPH (58 female, age 46+/-2 years, median NYHA class III) between 1996 and 2001 who were followed up in a tertiary referral center. Right heart catheterization was performed and serum uric acid levels were measured in all patients. Seventy patients were able to undergo exercise testing. At the start of the study, the average pulmonary artery pressure was 60+/-2 mm Hg, average pulmonary vascular resistance was 1664+/-81 dyne x s x cm(-5), average serum uric acid level was 7.5+/-0.35 mg/dL, and average peak oxygen uptake during exercise (peak VO(2) was 11.2+/-0.5 mL x kg(-1) x min(-1). During follow-up (mean: 567+/-48 days), 28 patients died and 16 underwent lung transplantation (1-year cumulative event-free survival: 68%; 95% CI 58 to 78). The strongest predictors of impaired survival were low peak VO(2) (P<0.0001) and low systolic blood pressure at peak exercise (peak SBP; P<0.0001). In a multivariable analysis, serum uric acid levels (all P<0.005) and diastolic blood pressure at peak exercise independently predicted survival (P<0.05). Patients with peak VO(2) < or =10.4 mL x kg(-1) x min(-1) and peak SBP < or =120 mm Hg (ie, 2 risk factors) had poor survival rates at 12 months (23%), whereas patients with 1 or none of these risk factors had better survival rates (79% and 97%, respectively).
CONCLUSIONS: Peak VO(2) and peak SBP are independent and strong predictors of survival in PPH patients. Hemodynamic parameters, although also accurate predictors, provide no independent prognostic information.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119247     DOI: 10.1161/01.cir.0000022687.18568.2a

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  94 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 2.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

3.  Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension.

Authors:  G Valli; C D Vizza; P Onorati; R Badagliacca; R Ciuffa; R Poscia; F Brandimarte; F Fedele; P Serra; P Palange
Journal:  Eur J Appl Physiol       Date:  2007-11-03       Impact factor: 3.078

4.  [Diagnosis and therapy of chronic pulmonary hypertension].

Authors:  Horst Olschewski; M M Hoeper; M M Borst; R Ewert; E Grünig; F-X Kleber; B Kopp; C Opitz; F Reichenberger; A Schmeisser; D Schranz; I Schulze-Neick; H Wilkens; J Winkler; H Worth
Journal:  Clin Res Cardiol       Date:  2007-05       Impact factor: 5.460

5.  Detection of exercise-induced pulmonary arterial hypertension by cardiopulmonary exercise testing.

Authors:  Martin Schwaiblmair; Christian Faul; Wolfgang von Scheidt; Thomas M Berghaus
Journal:  Clin Cardiol       Date:  2012-05-15       Impact factor: 2.882

6.  Effects of a preoperative individualized exercise program on selected recovery variables for cardiac surgery patients: A pilot study.

Authors:  Heng-Hsin Tung; Shu-Fen Shen; Chun-Che Shih; Kuan-Ming Chiu; Jyun-Yi Lee; Chieh-Yu Liu
Journal:  J Saudi Heart Assoc       Date:  2012-03-09

7.  Are transcutaneous oxygen and carbon dioxide determinations of value in pulmonary arterial hypertension?

Authors:  Adriano R Tonelli; Laith Alkukhun; Frank Cikach; Mostafa Ahmed; Raed A Dweik
Journal:  Microcirculation       Date:  2015-05       Impact factor: 2.628

Review 8.  [Therapy of pulmonary arterial hypertension].

Authors:  R Voswinckel; F Reichenberger; H Gall; W Seeger; F Grimminger; H A Ghofrani
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

9.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

10.  Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Hui-Juan Ni; Tian-Xiang Chen; Bigyan Pudasaini; Rong Jiang; Hui Liu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Jin-Ming Liu
Journal:  Hypertens Res       Date:  2017-06-01       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.